哮喘联盟

   摘要
   代谢综合征(MetS)是一个涉及至少3种代谢紊乱(血脂异常、胰岛素抵抗、肥胖和/或高血压)的综合征。已知MetS在成年期与几个慢性疾病相关联；然而，近些年，该综合征在儿童中被重新定义。初潮早和哮喘的女孩、以及MetS和哮喘的儿童在成年期似乎具有更高的严重或难以控制的哮喘发生风险，并且具有更高的心血管疾病患病几率。目前认为MetS和内分泌紊乱的患者具有不同的本质，药物治疗应该根据个体进行调整。该领域的最新专利文献论述了随着哮喘治疗如何管理内分泌控制的新问题。在不久的将来，新方法将减少与这类患者相关的高发病率和病死率。
 

（林江涛 审校）
Recent Pat Endocr Metab Immune Drug Discov. 2014 Jan 7. [Epub ahead of print]

 

Metabolic Syndrome and Asthma.
 

Garmendia JV, Moreno D, García AH, De Sanctis JB.
 

Abstract
Metabolic syndrome (MetS) is a syndrome that involves at least three disorders dyslipidemia, insulin resistance, obesity and/or hypertension. MetS has been associated with several chronic diseases in the adulthood; however, in the recent years, the syndrome was redefined in children. Girls with early menarche and asthma, and children with MetS and asthma that reach adulthood appear to have higher risk to develop severe or difficult to control asthma and a higher probability to suffer cardiovascular diseases. It has been proposed that patients with MetS and endocrinological disorders should be considered a different entity in which pharmacologic treatment should be adjusted according to the individual. Recent patents on the field have addressed new issues on how endocrine control should be managed along with asthma therapeutics. In the near future, new approaches should decrease the high morbidity and mortality associated to these types of patients.
 

Recent Pat Endocr Metab Immune Drug Discov. 2014 Jan 7. [Epub ahead of print]